25 XP   0   0   10

UroGen Pharma Ltd
Buy, Hold or Sell?

Let's analyse Urogen together

PenkeI guess you are interested in UroGen Pharma Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of UroGen Pharma Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about UroGen Pharma Ltd

I send you an email if I find something interesting about UroGen Pharma Ltd.

Quick analysis of Urogen (30 sec.)










What can you expect buying and holding a share of Urogen? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.80
Expected worth in 1 year
$-1.01
How sure are you?
21.9%

+ What do you gain per year?

Total Gains per Share
$0.80
Return On Investment
5.8%

For what price can you sell your share?

Current Price per Share
$13.73
Expected price per share
$10.63 - $19.87
How sure are you?
50%

1. Valuation of Urogen (5 min.)




Live pricePrice per Share (EOD)

$13.73

Intrinsic Value Per Share

$-5.99 - $-6.14

Total Value Per Share

$-7.79 - $-7.95

2. Growth of Urogen (5 min.)




Is Urogen growing?

Current yearPrevious yearGrowGrow %
How rich?-$65.2m-$52.5m-$38m-42.0%

How much money is Urogen making?

Current yearPrevious yearGrowGrow %
Making money-$25.5m-$27.2m$1.7m6.8%
Net Profit Margin-126.4%-171.7%--

How much money comes from the company's main activities?

3. Financial Health of Urogen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#993 / 1016

Most Revenue
#232 / 1016

Most Profit
#753 / 1016

Most Efficient
#593 / 1016

What can you expect buying and holding a share of Urogen? (5 min.)

Welcome investor! Urogen's management wants to use your money to grow the business. In return you get a share of Urogen.

What can you expect buying and holding a share of Urogen?

First you should know what it really means to hold a share of Urogen. And how you can make/lose money.

Speculation

The Price per Share of Urogen is $13.73. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Urogen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Urogen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.80. Based on the TTM, the Book Value Change Per Share is $0.20 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.71 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Urogen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.72-5.2%-0.74-5.4%-0.80-5.9%-0.81-5.9%-0.61-4.4%
Usd Book Value Change Per Share-0.57-4.2%0.201.5%-0.71-5.2%-0.22-1.6%-0.06-0.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.57-4.2%0.201.5%-0.71-5.2%-0.22-1.6%-0.06-0.4%
Usd Price Per Share15.00-12.15-8.52-17.76-19.74-
Price to Earnings Ratio-5.21--4.24--2.65--5.66--3.64-
Price-to-Total Gains Ratio-26.17--12.17--11.99--27.66--22.95-
Price to Book Ratio-8.32--6.24--8.03-3.03-5.07-
Price-to-Total Gains Ratio-26.17--12.17--11.99--27.66--22.95-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.73
Number of shares72
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.20-0.22
Usd Total Gains Per Share0.20-0.22
Gains per Quarter (72 shares)14.34-16.00
Gains per Year (72 shares)57.38-63.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1057470-64-74
201151040-128-138
301721610-192-202
402302180-256-266
502872750-320-330
603443320-384-394
704023890-448-458
804594460-512-522
905165030-576-586
1005745600-640-650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%3.029.00.09.4%3.029.00.09.4%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%7.022.03.021.9%7.022.03.021.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.032.00.0%0.00.032.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%7.022.03.021.9%7.022.03.021.9%

Fundamentals of Urogen

About UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Fundamental data was last updated by Penke on 2024-04-12 21:08:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of UroGen Pharma Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Urogen earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Urogen to the Biotechnology industry mean.
  • A Net Profit Margin of -110.6% means that $-1.11 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of UroGen Pharma Ltd:

  • The MRQ is -110.6%. The company is making a huge loss. -2
  • The TTM is -126.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-110.6%TTM-126.4%+15.8%
TTM-126.4%YOY-171.7%+45.3%
TTM-126.4%5Y-6,834.9%+6,708.5%
5Y-6,834.9%10Y-5,993.7%-841.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-110.6%-199.6%+89.0%
TTM-126.4%-213.0%+86.6%
YOY-171.7%-279.3%+107.6%
5Y-6,834.9%-438.4%-6,396.5%
10Y-5,993.7%-605.5%-5,388.2%
1.1.2. Return on Assets

Shows how efficient Urogen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Urogen to the Biotechnology industry mean.
  • -14.6% Return on Assets means that Urogen generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of UroGen Pharma Ltd:

  • The MRQ is -14.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.6%TTM-19.5%+4.9%
TTM-19.5%YOY-19.1%-0.4%
TTM-19.5%5Y-18.9%-0.5%
5Y-18.9%10Y-17.2%-1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.6%-13.5%-1.1%
TTM-19.5%-12.9%-6.6%
YOY-19.1%-11.8%-7.3%
5Y-18.9%-14.1%-4.8%
10Y-17.2%-16.0%-1.2%
1.1.3. Return on Equity

Shows how efficient Urogen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Urogen to the Biotechnology industry mean.
  • 0.0% Return on Equity means Urogen generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of UroGen Pharma Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-33.4%+33.4%
5Y-33.4%10Y-26.7%-6.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY--15.1%+15.1%
5Y-33.4%-19.9%-13.5%
10Y-26.7%-20.9%-5.8%

1.2. Operating Efficiency of UroGen Pharma Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Urogen is operating .

  • Measures how much profit Urogen makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Urogen to the Biotechnology industry mean.
  • An Operating Margin of -62.1% means the company generated $-0.62  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of UroGen Pharma Ltd:

  • The MRQ is -62.1%. The company is operating very inefficient. -2
  • The TTM is -80.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-62.1%TTM-80.4%+18.3%
TTM-80.4%YOY-124.8%+44.4%
TTM-80.4%5Y-7,164.7%+7,084.3%
5Y-7,164.7%10Y-6,212.7%-952.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-62.1%-295.1%+233.0%
TTM-80.4%-225.8%+145.4%
YOY-124.8%-288.4%+163.6%
5Y-7,164.7%-477.4%-6,687.3%
10Y-6,212.7%-625.6%-5,587.1%
1.2.2. Operating Ratio

Measures how efficient Urogen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.62 means that the operating costs are $1.62 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of UroGen Pharma Ltd:

  • The MRQ is 1.621. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.820. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.621TTM1.820-0.199
TTM1.820YOY2.248-0.428
TTM1.8205Y72.487-70.667
5Y72.48710Y67.719+4.768
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6213.090-1.469
TTM1.8203.264-1.444
YOY2.2483.783-1.535
5Y72.4875.679+66.808
10Y67.7197.894+59.825

1.3. Liquidity of UroGen Pharma Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Urogen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.42 means the company has $5.42 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of UroGen Pharma Ltd:

  • The MRQ is 5.421. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.831. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.421TTM4.831+0.589
TTM4.831YOY6.985-2.153
TTM4.8315Y8.002-3.171
5Y8.00210Y8.649-0.646
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4213.914+1.507
TTM4.8314.220+0.611
YOY6.9855.388+1.597
5Y8.0026.045+1.957
10Y8.6496.406+2.243
1.3.2. Quick Ratio

Measures if Urogen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Urogen to the Biotechnology industry mean.
  • A Quick Ratio of 6.25 means the company can pay off $6.25 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of UroGen Pharma Ltd:

  • The MRQ is 6.254. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.281. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.254TTM5.281+0.973
TTM5.281YOY8.372-3.091
TTM5.2815Y10.633-5.352
5Y10.63310Y10.143+0.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2543.572+2.682
TTM5.2813.998+1.283
YOY8.3725.390+2.982
5Y10.6335.969+4.664
10Y10.1436.287+3.856

1.4. Solvency of UroGen Pharma Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Urogen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Urogen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.37 means that Urogen assets are financed with 136.6% credit (debt) and the remaining percentage (100% - 136.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of UroGen Pharma Ltd:

  • The MRQ is 1.366. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.767. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.366TTM1.767-0.401
TTM1.767YOY1.382+0.385
TTM1.7675Y0.799+0.967
5Y0.79910Y0.550+0.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3660.336+1.030
TTM1.7670.334+1.433
YOY1.3820.269+1.113
5Y0.7990.366+0.433
10Y0.5500.390+0.160
1.4.2. Debt to Equity Ratio

Measures if Urogen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Urogen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of UroGen Pharma Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.974-0.974
5Y0.97410Y0.671+0.303
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.396-0.396
YOY-0.335-0.335
5Y0.9740.434+0.540
10Y0.6710.465+0.206

2. Market Valuation of UroGen Pharma Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Urogen generates.

  • Above 15 is considered overpriced but always compare Urogen to the Biotechnology industry mean.
  • A PE ratio of -5.21 means the investor is paying $-5.21 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of UroGen Pharma Ltd:

  • The EOD is -4.770. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.211. Based on the earnings, the company is expensive. -2
  • The TTM is -4.235. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.770MRQ-5.211+0.441
MRQ-5.211TTM-4.235-0.976
TTM-4.235YOY-2.651-1.584
TTM-4.2355Y-5.659+1.424
5Y-5.65910Y-3.635-2.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.770-2.259-2.511
MRQ-5.211-2.569-2.642
TTM-4.235-2.664-1.571
YOY-2.651-4.120+1.469
5Y-5.659-6.258+0.599
10Y-3.635-6.171+2.536
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of UroGen Pharma Ltd:

  • The EOD is -9.466. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.342. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.153. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.466MRQ-10.342+0.876
MRQ-10.342TTM-6.153-4.188
TTM-6.153YOY-3.361-2.792
TTM-6.1535Y-7.760+1.606
5Y-7.76010Y-9.986+2.227
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.466-2.924-6.542
MRQ-10.342-3.246-7.096
TTM-6.153-3.488-2.665
YOY-3.361-5.620+2.259
5Y-7.760-8.315+0.555
10Y-9.986-8.826-1.160
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Urogen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -8.32 means the investor is paying $-8.32 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of UroGen Pharma Ltd:

  • The EOD is -7.612. Based on the equity, the company is expensive. -2
  • The MRQ is -8.316. Based on the equity, the company is expensive. -2
  • The TTM is -6.239. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.612MRQ-8.316+0.704
MRQ-8.316TTM-6.239-2.077
TTM-6.239YOY-8.033+1.794
TTM-6.2395Y3.033-9.272
5Y3.03310Y5.066-2.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.6121.851-9.463
MRQ-8.3162.090-10.406
TTM-6.2392.095-8.334
YOY-8.0332.844-10.877
5Y3.0333.466-0.433
10Y5.0663.815+1.251
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of UroGen Pharma Ltd.

3.1. Funds holding UroGen Pharma Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29CS (Lux) Digital Health Equity SB USD3.69341.4122120000000
2024-02-29iShares Russell 2000 ETF2.02610.0194658275-108-0.0164
2023-11-30MEDICAL BioHealth EUR Acc1.64061.07345330276610814.1583
2023-12-31Fidelity Small Cap Index0.83510.0162713147774140.1611
2024-01-31APO Medical Opportunities R0.67170.421921823300
2024-02-29iShares Biotechnology ETF0.62430.0489202822-915-0.4491
2024-02-29iShares Russell 2000 Growth ETF0.60060.0315195150-227-0.1162
2023-12-31AlphaCentric LifeSci Healthcare I0.47712.2305155000-10000-6.0606
2024-02-29ARK Israel Innovative Technology ETF0.45692.414214844100
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.39770.005712920000
2024-02-29SPDR® Portfolio Developed Wld ex-US ETF0.35440.01111516000
2024-02-29Vanguard Russell 2000 ETF0.30470.0199899678328.5911
2023-12-31RIM Global Bioscience EUR0.24221.12087868000
2024-02-29VT De Lisle America B USD0.24110.34647832750006.8188
2023-12-31NT R2000 Index Fund - NL0.23880.0161775832244140.6967
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.22190.0147210000
2023-12-31NT R2000 Growth Index Fund - NL0.20440.0269663971837238.2551
2024-02-29Schwab Small Cap Index0.19350.01956288000
2024-02-29iShares Micro-Cap ETF0.18840.12316121600
2023-12-31NT R2000 Index Fund - DC - NL - 20.1880.0161610971750540.1565
Total 13.80099.38664483898+203749+4.5%

3.2. Insider Transactions

Insiders are holding 11.351% of the shares of UroGen Pharma Ltd.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-18Mark SchoenbergSELL1200014.05
2024-01-31Jason Drew SmithSELL499315.74
2024-01-31Mark SchoenbergSELL378915.74
2023-08-31Jason Drew SmithSELL380018.01

4. Summary

4.1. Key Performance Indicators

The key performance indicators of UroGen Pharma Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.5730.199-388%-0.712+24%-0.222-61%-0.056-90%
Book Value Per Share---1.804-2.627+46%-1.539-15%1.421-227%1.558-216%
Current Ratio--5.4214.831+12%6.985-22%8.002-32%8.649-37%
Debt To Asset Ratio--1.3661.767-23%1.382-1%0.799+71%0.550+149%
Debt To Equity Ratio----0%-0%0.974-100%0.671-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.720-0.738+3%-0.804+12%-0.813+13%-0.608-16%
Free Cash Flow Per Share---0.363-0.556+53%-0.643+77%-0.627+73%-0.437+20%
Free Cash Flow To Equity Per Share---0.3530.303-216%0.068-616%0.060-692%0.129-372%
Gross Profit Margin--1.0001.0000%1.0000%1.084-8%1.052-5%
Intrinsic Value_10Y_max---6.142--------
Intrinsic Value_10Y_min---5.987--------
Intrinsic Value_1Y_max---2.175--------
Intrinsic Value_1Y_min---2.138--------
Intrinsic Value_3Y_max---5.347--------
Intrinsic Value_3Y_min---5.129--------
Intrinsic Value_5Y_max---7.086--------
Intrinsic Value_5Y_min---6.679--------
Market Cap468496433.000-16%542304510.000422201767.500+28%290805597.250+86%607395658.100-11%674490546.094-20%
Net Profit Margin---1.106-1.264+14%-1.717+55%-68.349+6082%-59.937+5321%
Operating Margin---0.621-0.804+29%-1.248+101%-71.647+11440%-62.127+9906%
Operating Ratio--1.6211.820-11%2.248-28%72.487-98%67.719-98%
Pb Ratio-7.612+8%-8.316-6.239-25%-8.033-3%3.033-374%5.066-264%
Pe Ratio-4.770+8%-5.211-4.235-19%-2.651-49%-5.659+9%-3.635-30%
Price Per Share13.730-9%15.00012.150+23%8.523+76%17.756-16%19.739-24%
Price To Free Cash Flow Ratio-9.466+8%-10.342-6.153-40%-3.361-67%-7.760-25%-9.986-3%
Price To Total Gains Ratio-23.958+8%-26.174-12.174-53%-11.991-54%-27.663+6%-22.953-12%
Quick Ratio--6.2545.281+18%8.372-25%10.633-41%10.143-38%
Return On Assets---0.146-0.195+34%-0.191+31%-0.189+30%-0.172+18%
Return On Equity----0%-0%-0.3340%-0.2670%
Total Gains Per Share---0.5730.199-388%-0.712+24%-0.222-61%-0.056-90%
Usd Book Value---65212000.000-90548250.000+39%-52503500.000-19%48304450.000-235%53046500.000-223%
Usd Book Value Change Per Share---0.5730.199-388%-0.712+24%-0.222-61%-0.056-90%
Usd Book Value Per Share---1.804-2.627+46%-1.539-15%1.421-227%1.558-216%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.720-0.738+3%-0.804+12%-0.813+13%-0.608-16%
Usd Free Cash Flow---13109507.000-19156876.750+46%-21953250.000+67%-21426375.350+63%-14923265.844+14%
Usd Free Cash Flow Per Share---0.363-0.556+53%-0.643+77%-0.627+73%-0.437+20%
Usd Free Cash Flow To Equity Per Share---0.3530.303-216%0.068-616%0.060-692%0.129-372%
Usd Market Cap468496433.000-16%542304510.000422201767.500+28%290805597.250+86%607395658.100-11%674490546.094-20%
Usd Price Per Share13.730-9%15.00012.150+23%8.523+76%17.756-16%19.739-24%
Usd Profit---26016000.000-25561000.000-2%-27290750.000+5%-27792850.000+7%-20705187.500-20%
Usd Revenue--23530000.00020678250.000+14%16089250.000+46%10346450.000+127%7332125.000+221%
Usd Total Gains Per Share---0.5730.199-388%-0.712+24%-0.222-61%-0.056-90%
 EOD+2 -6MRQTTM+22 -9YOY+22 -95Y+16 -1710Y+13 -20

4.2. Fundamental Score

Let's check the fundamental score of UroGen Pharma Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.770
Price to Book Ratio (EOD)Between0-1-7.612
Net Profit Margin (MRQ)Greater than0-1.106
Operating Margin (MRQ)Greater than0-0.621
Quick Ratio (MRQ)Greater than16.254
Current Ratio (MRQ)Greater than15.421
Debt to Asset Ratio (MRQ)Less than11.366
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.146
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of UroGen Pharma Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose14.060
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -10762-45-109-15420-13414612



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets178,311
Total Liabilities243,523
Total Stockholder Equity-65,212
 As reported
Total Liabilities 243,523
Total Stockholder Equity+ -65,212
Total Assets = 178,311

Assets

Total Assets178,311
Total Current Assets169,186
Long-term Assets9,125
Total Current Assets
Cash And Cash Equivalents 95,823
Short-term Investments 41,966
Net Receivables 15,443
Inventory 5,673
Other Current Assets 10,281
Total Current Assets  (as reported)169,186
Total Current Assets  (calculated)169,186
+/-0
Long-term Assets
Property Plant Equipment 2,360
Long Term Investments 4,502
Long-term Assets Other 2,038
Long-term Assets  (as reported)9,125
Long-term Assets  (calculated)8,900
+/- 225

Liabilities & Shareholders' Equity

Total Current Liabilities31,212
Long-term Liabilities212,311
Total Stockholder Equity-65,212
Total Current Liabilities
Short-term Debt 819
Accounts payable 6,514
Other Current Liabilities 19,488
Total Current Liabilities  (as reported)31,212
Total Current Liabilities  (calculated)26,821
+/- 4,391
Long-term Liabilities
Long term Debt 98,551
Capital Lease Obligations 844
Long-term Liabilities  (as reported)212,311
Long-term Liabilities  (calculated)99,395
+/- 112,916
Total Stockholder Equity
Common Stock89
Retained Earnings -679,348
Accumulated Other Comprehensive Income 12
Other Stockholders Equity 614,035
Total Stockholder Equity (as reported)-65,212
Total Stockholder Equity (calculated)-65,212
+/-0
Other
Capital Stock89
Cash and Short Term Investments 137,789
Common Stock Shares Outstanding 36,154
Current Deferred Revenue4,391
Liabilities and Stockholders Equity 178,311
Net Debt 4,391
Net Invested Capital 33,339
Net Working Capital 137,974
Property Plant and Equipment Gross 6,312
Short Long Term Debt Total 100,214



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
> Total Assets 
19,390
0
0
23,056
0
79,038
81,188
75,550
129,402
121,502
112,558
103,559
252,052
238,566
226,753
202,388
166,929
161,077
139,893
122,005
97,414
153,768
134,603
119,746
165,715
146,141
128,473
136,239
112,954
95,361
193,633
178,311
178,311193,63395,361112,954136,239128,473146,141165,715119,746134,603153,76897,414122,005139,893161,077166,929202,388226,753238,566252,052103,559112,558121,502129,40275,55081,18879,038023,0560019,390
   > Total Current Assets 
19,131
0
0
22,041
0
78,302
80,449
74,472
128,736
120,704
111,471
102,243
248,295
191,194
159,876
148,634
121,866
129,943
129,338
115,619
93,082
140,498
125,140
114,390
160,524
139,624
121,594
128,907
95,973
81,333
182,123
169,186
169,186182,12381,33395,973128,907121,594139,624160,524114,390125,140140,49893,082115,619129,338129,943121,866148,634159,876191,194248,295102,243111,471120,704128,73674,47280,44978,302022,0410019,131
       Cash And Cash Equivalents 
17,975
0
0
21,362
0
77,093
79,171
36,999
127,460
119,109
109,483
101,318
246,692
90,424
66,147
49,688
26,468
36,350
24,565
103,911
40,492
63,322
55,337
44,360
105,379
80,690
28,686
55,408
36,540
20,127
119,305
95,823
95,823119,30520,12736,54055,40828,68680,690105,37944,36055,33763,32240,492103,91124,56536,35026,46849,68866,14790,424246,692101,318109,483119,109127,46036,99979,17177,093021,3620017,975
       Short-term Investments 
21
0
0
95
0
97
197
36,001
197
197
197
0
0
98,739
92,046
97,389
92,623
88,773
95,058
49,154
35,417
57,710
50,872
44,779
31,065
31,048
67,225
44,556
28,514
27,174
28,114
41,966
41,96628,11427,17428,51444,55667,22531,04831,06544,77950,87257,71035,41749,15495,05888,77392,62397,38992,04698,7390019719719736,001197970950021
       Net Receivables 
0
0
0
83
0
10
34
198
4
232
112
0
0
0
0
0
0
402
2,810
7,047
6,301
9,512
7,784
11,717
9,499
11,595
9,429
12,704
12,493
15,505
12,847
15,443
15,44312,84715,50512,49312,7049,42911,5959,49911,7177,7849,5126,3017,0472,81040200000011223241983410083000
       Other Current Assets 
1,135
0
0
396
0
704
910
958
726
1,024
1,679
672
1,196
1,724
1,160
1,034
1,552
2,069
4,335
3,364
6,316
5,308
6,113
7,476
9,275
10,433
10,580
11,101
12,146
12,723
16,038
10,281
10,28116,03812,72312,14611,10110,58010,4339,2757,4766,1135,3086,3163,3644,3352,0691,5521,0341,1601,7241,1966721,6791,0247269589107040396001,135
   > Long-term Assets 
0
0
0
1,015
0
736
739
1,078
666
798
1,087
1,316
3,757
47,372
66,877
53,754
45,063
31,134
10,555
6,386
4,332
13,270
9,463
5,356
5,191
6,517
6,879
6,712
16,981
14,028
11,510
9,125
9,12511,51014,02816,9816,7126,8796,5175,1915,3569,46313,2704,3326,38610,55531,13445,06353,75466,87747,3723,7571,3161,0877986661,07873973601,015000
       Property Plant Equipment 
259
0
0
741
0
707
710
805
637
718
992
948
3,706
3,466
3,316
4,712
4,424
4,412
4,377
4,204
4,043
3,654
3,396
3,147
2,722
3,721
4,185
3,749
3,432
3,017
2,728
2,360
2,3602,7283,0173,4323,7494,1853,7212,7223,1473,3963,6544,0434,2044,3774,4124,4244,7123,3163,4663,706948992718637805710707074100259
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
43,851
63,506
48,555
40,137
26,499
5,900
1,893
0
8,290
4,071
675
674
673
0
0
10,165
7,970
6,507
4,502
4,5026,5077,97010,165006736746754,0718,29001,8935,90026,49940,13748,55563,50643,8510000000000000
       Other Assets 
0
0
0
274
0
29
29
273
29
80
95
368
51
55
55
487
502
223
278
289
289
1,326
1,996
30
1,795
40,247
2,694
620
0
3,041
0
0
003,04106202,69440,2471,795301,9961,32628928927822350248755555136895802927329290274000
> Total Liabilities 
3,109
0
0
6,749
0
4,966
4,927
7,035
5,535
7,952
8,975
13,465
12,461
13,787
15,837
22,086
16,475
18,417
19,366
25,650
20,923
97,497
103,066
111,333
182,789
187,054
191,759
224,980
229,508
233,795
235,626
243,523
243,523235,626233,795229,508224,980191,759187,054182,789111,333103,06697,49720,92325,65019,36618,41716,47522,08615,83713,78712,46113,4658,9757,9525,5357,0354,9274,96606,749003,109
   > Total Current Liabilities 
2,237
0
0
3,137
0
4,966
4,927
7,035
5,535
7,952
8,975
13,465
10,277
11,844
14,088
19,482
14,207
16,423
17,618
21,436
17,005
19,056
19,806
22,380
19,091
18,040
18,999
23,916
25,234
26,765
25,788
31,212
31,21225,78826,76525,23423,91618,99918,04019,09122,38019,80619,05617,00521,43617,61816,42314,20719,48214,08811,84410,27713,4658,9757,9525,5357,0354,9274,96603,137002,237
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,001
1,067
1,126
0
1,632
1,476
1,335
0
0
0
0
0
0
817
940
941
968
910
858
819
8198589109689419408170000001,3351,4761,63201,1261,0671,001000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,001
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,001000000000000
       Accounts payable 
1,728
0
0
1,880
0
3,543
3,488
4,435
4,048
5,655
6,291
8,540
1,700
2,101
2,638
4,694
4,152
4,598
4,134
3,271
6,096
4,830
4,060
5,786
4,234
2,457
2,545
5,527
6,968
4,659
4,041
6,514
6,5144,0414,6596,9685,5272,5452,4574,2345,7864,0604,8306,0963,2714,1344,5984,1524,6942,6382,1011,7008,5406,2915,6554,0484,4353,4883,54301,880001,728
       Other Current Liabilities 
509
0
0
1,257
0
1,112
1,139
1,950
1,291
2,211
2,684
4,925
7,576
8,676
10,324
14,788
8,423
10,349
12,149
18,165
10,909
14,226
15,746
16,594
14,857
14,087
14,827
16,830
15,652
18,475
18,179
19,488
19,48818,17918,47515,65216,83014,82714,08714,85716,59415,74614,22610,90918,16512,14910,3498,42314,78810,3248,6767,5764,9252,6842,2111,2911,9501,1391,11201,25700509
   > Long-term Liabilities 
0
0
0
3,612
0
0
0
0
0
0
0
0
2,184
1,943
1,749
2,604
2,268
1,994
1,748
4,214
3,918
78,441
83,260
88,953
163,698
169,014
172,760
201,064
204,274
207,030
209,838
212,311
212,311209,838207,030204,274201,064172,760169,014163,69888,95383,26078,4413,9184,2141,7481,9942,2682,6041,7491,9432,184000000003,612000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70,797
0
0
0
97,941
0
0
0
00097,94100070,797000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
2,184
0
0
0
0
0
0
2,717
2,717
77,519
82,644
88,555
92,624
96,303
99,034
0
0
107,525
0
0
00107,5250099,03496,30392,62488,55582,64477,5192,7172,7170000002,184000000000000
> Total Stockholder Equity
16,281
0
0
16,307
16,303
74,072
76,261
68,515
123,867
113,550
103,583
90,094
239,591
224,779
210,916
180,302
150,454
142,660
120,527
96,355
76,491
56,271
31,537
8,413
-17,074
-40,913
-63,286
-88,741
-116,554
-138,434
-41,993
-65,212
-65,212-41,993-138,434-116,554-88,741-63,286-40,913-17,0748,41331,53756,27176,49196,355120,527142,660150,454180,302210,916224,779239,59190,094103,583113,550123,86768,51576,26174,07216,30316,3070016,281
   Common Stock
6
0
0
6
0
35
35
37
42
43
44
44
56
57
57
57
58
60
60
60
61
61
61
61
62
62
63
63
64
64
84
89
89846464636362626161616160606058575757564444434237353506006
   Retained Earnings Total Equity00-631,453-607,317-577,104-548,235-522,404-495,713-467,321-438,869-408,658-382,436-356,501-325,975-297,159-265,810-228,017-189,044-166,792-144,315-122,87100000000000
   Accumulated Other Comprehensive Income 
0
0
0
-370
0
0
0
-577
0
0
0
-747
-804
281
303
276
311
760
492
271
143
45
4
-25
-69
-56
-155
-107
-45
-154
-134
12
12-134-154-45-107-155-56-69-25445143271492760311276303281-804-747000-577000-370000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
212,921
383,850
391,233
399,600
407,986
415,895
438,999
445,950
452,525
458,723
464,823
470,341
475,698
478,646
481,485
485,041
487,787
490,744
493,109
0
0
00493,109490,744487,787485,041481,485478,646475,698470,341464,823458,723452,525445,950438,999415,895407,986399,600391,233383,850212,92100000000000
   Treasury Stock00000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
43,872
0
110,867
113,354
116,269
184,421
192,129
202,693
213,668
384,654
391,233
399,600
407,986
415,895
438,999
445,950
452,525
458,723
464,823
470,341
475,759
478,646
481,485
485,041
488,407
490,744
493,109
611,389
614,035
614,035611,389493,109490,744488,407485,041481,485478,646475,759470,341464,823458,723452,525445,950438,999415,895407,986399,600391,233384,654213,668202,693192,129184,421116,269113,354110,867043,872000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue82,713
Cost of Revenue-9,361
Gross Profit73,35273,352
 
Operating Income (+$)
Gross Profit73,352
Operating Expense-138,888
Operating Income-65,536-65,536
 
Operating Expense (+$)
Research Development45,614
Selling General Administrative90,357
Selling And Marketing Expenses0
Operating Expense138,888135,971
 
Net Interest Income (+$)
Interest Income2,384
Interest Expense-36,267
Other Finance Cost-21,987
Net Interest Income-11,896
 
Pretax Income (+$)
Operating Income-65,536
Net Interest Income-11,896
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-98,324-32,748
EBIT - interestExpense = -101,803
-98,324
-65,977
Interest Expense36,267
Earnings Before Interest and Taxes (EBIT)-65,536-62,057
Earnings Before Interest and Taxes (EBITDA)-63,831
 
After tax Income (+$)
Income Before Tax-98,324
Tax Provision-755
Net Income From Continuing Ops-105,097-99,079
Net Income-102,244
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses148,249
Total Other Income/Expenses Net-32,78811,896
 

Technical Analysis of Urogen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Urogen. The general trend of Urogen is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Urogen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of UroGen Pharma Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 16.30 < 18.23 < 19.87.

The bearish price targets are: 12.37 > 10.92 > 10.63.

Tweet this
UroGen Pharma Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of UroGen Pharma Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

UroGen Pharma Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Moving Average Convergence/Divergence (MACD) ChartUroGen Pharma Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of UroGen Pharma Ltd. The current adx is .

UroGen Pharma Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Relative Strength Index (RSI) ChartUroGen Pharma Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Stochastic Oscillator ChartUroGen Pharma Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Commodity Channel Index (CCI) ChartUroGen Pharma Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Chande Momentum Oscillator (CMO) ChartUroGen Pharma Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Williams %R ChartUroGen Pharma Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Average True Range (ATR) ChartUroGen Pharma Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily On-Balance Volume (OBV) ChartUroGen Pharma Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of UroGen Pharma Ltd.

UroGen Pharma Ltd Daily Money Flow Index (MFI) ChartUroGen Pharma Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for UroGen Pharma Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

UroGen Pharma Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of UroGen Pharma Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose14.060
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Urogen with someone you think should read this too:
  • Are you bullish or bearish on Urogen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Urogen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about UroGen Pharma Ltd

I send you an email if I find something interesting about UroGen Pharma Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about UroGen Pharma Ltd.

Receive notifications about UroGen Pharma Ltd in your mailbox!